Severe cutaneous adverse reactions
Nature Reviews Disease Primers · 25.04.2024 · 10 (1)
DOI: 10.1038/s41572-024-00514-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Disease Primers, online erschienen am 25.04.2024. Verfasst von Shuen-Iu Hung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 306 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Severe cutaneous adverse reactions (SCARs), which include Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also known as drug-induced hypersensitivity syndrome), acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption, are life-threatening conditions. The pathogenesis of SCARs involves T cell receptors recognizing drug antigens presented by human leukocyte antigens, triggering the activation of distinct T cell subsets. These cells interact with keratinocytes and various immune cells, orchestrating cutaneous lesions and systemic manifestations. Genetic predisposition, impaired drug metabolism, viral reactivation or infections, and heterologous immunity influence SCAR development and clinical presentation. Specific genetic associations with distinct SCAR phenotypes have been identified, leading to the implementation of genetic screening before prescription in various countries to prevent SCARs. Whilst systemic corticosteroids and conventional immunomodulators have been the primary therapeutic agents, evolving strategies, including biologics and small molecules targeting tumour necrosis factor, different cytokines, or Janus kinase signalling pathways, signify a shift towards a precision management paradigm that considers individual clinical presentations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
- Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty, University of Freiburg, Freiburg, Germany.
- Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
ORCID-Profile: Shuen-Iu Hung, Wen-Hung Chung
Förderung
- NIAID NIH HHS
Zitieren
APA
Hung, S. I., Mockenhaupt, M., Blumenthal, K. G., Abe, R., Ueta, M., Ingen-Housz-Oro, S., Phillips, E. J., & Chung, W. H. (2024). Severe cutaneous adverse reactions. Nature Reviews Disease Primers, 10(1). https://doi.org/10.1038/s41572-024-00514-0
Vancouver
Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, et al. Severe cutaneous adverse reactions. Nature Reviews Disease Primers. 2024;10(1). doi:10.1038/s41572-024-00514-0
BibTeX
@article{Hung2024,
author = {Hung, Shuen-Iu and Mockenhaupt, Maja and Blumenthal, Kimberly G and Abe, Riichiro and Ueta, Mayumi and Ingen-Housz-Oro, Saskia and Phillips, Elizabeth J and Chung, Wen-Hung},
title = {Severe cutaneous adverse reactions},
journal = {Nature Reviews Disease Primers},
year = {2024},
volume = {10},
number = {1},
doi = {10.1038/s41572-024-00514-0}
}
EUVIMED